Venetoclax
Brand name: Venclexta
Rank #73 of 500 drugs by total cost
$259.6M
Total Cost
28,191
Total Claims
$259.6M
Total Cost
1,181
Prescribers
$9,207
Cost per Claim
1,956
Beneficiaries
28,416
30-Day Fills
$220K
Avg Cost/Provider
24
Avg Claims/Provider
About Venetoclax
Venetoclax (sold as Venclexta) was prescribed 28,191 times by 1,181 Medicare Part D providers in 2023, costing the program $259.6M. At $9,207 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 70 | Immune Globul G/Gly/Iga Avg 46 (Gamunex-C) | $266.5M | 27,501 |
| 71 | Rosuvastatin Calcium (Rosuvastatin Calcium) | $264.9M | 11,259,701 |
| 72 | Risankizumab-Rzaa (Skyrizi Pen) | $259.7M | 12,539 |
| 73 | Venetoclax (Venclexta) | $259.6M | 28,191 |
| 74 | Zanubrutinib (Brukinsa) | $256.8M | 19,239 |
| 75 | Metoprolol Succinate (Metoprolol Succinate) | $256.3M | 12,847,535 |
| 76 | Dolutegravir Sodium (Tivicay) | $251.7M | 102,995 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology